With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.64519-82-0,(3R,4R,5R)-6-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexane-1,2,3,4,5-pentaol,as a common compound, the synthetic route is as follows.
General procedure: The donor component (1equiv), the acceptor substrate (2equiv), and alpha-galactosidase RafA (20U/mmol acceptor) were dissolved in potassium phosphate buffer (100muL, version A or version B) and incubated in a thermomixer for 24h at 37C. For termination the temperature was enhanced to 95C for 10min. Separation and purification of the products were done either on Biogel P2 with water as eluent or on Sephadex LH-20 with water/ethanol 1:5 as eluent. Version A for glycopyranosyl fluoride donors: 0.3M KH2PO4/K2HPO4, pH 6.5. Version B for other donors: 0.1M K2HPO4/K2HPO4, pH 6.5.
64519-82-0 (3R,4R,5R)-6-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexane-1,2,3,4,5-pentaol 88735, aTetrahydropyrans compound, is more and more widely used in various.
Reference£º
Article; Schroeder, Sven; Kroeger, Lars; Mattes, Ralf; Thiem, Joachim; Carbohydrate Research; vol. 403; (2015); p. 157 – 166;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics